NanoViricides Inc. Celebrated the Grand Opening of Its New R&D & cGMP Pilot Manufacturing Facility with Congressman Jim Himes...
July 22 2014 - 7:00AM
Business Wire
NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”) celebrated
the grand opening of its new R&D and cGMP pilot manufacturing
facility with Congressman Jim Himes as the Chief Guest yesterday,
July 21. In addition, Senator Chris Murphy and Senator Richard
Blumenthal sent delegates on their behalf while CT Governor Malloy
sent a congratulatory Proclamation and was represented by Cowlis
Andrews from CT’s Office of Business Development of the Department
of Economic and Community Development (DECD).
The dignitaries took a tour of the facility led by Dr. Anil
Diwan, President & Chairman of the Company. Congressman Himes
performed the ribbon cutting ceremony to inaugurate the facility.
Dr. Diwan then read the congratulatory Proclamation sent by
Governor Malloy to the Company and introduced the speakers.
Congressman Himes spoke about the potentially great impact that a
cutting edge nanomedicines pharmaceutical company like
NanoViricides, Inc. can have, not only in Connecticut’s regional
economic development but also in the service of humanity. He spoke
about Influenza and HIV in particular as being very difficult
diseases that continue to be devastating globally. He said that the
nanoviricides technology developed by the Company has the potential
to create effective drugs against these difficult diseases.
The delegate from Senators Murphy’s office presented a letter of
congratulations to the Company. Senator Murphy stated in the
letter: “This day brings with it the promise of high-skill jobs
creation here in Connecticut, the advancement of truly
groundbreaking medical technologies, and a continuation of
international respect that this organization (NanoViricides, Inc.)
has commanded since its founding.” The delegate from Senator
Blumenthal’s office conveyed the Senators’ good wishes and
congratulations to the Company. Bill Purcell, President of the
Greater Valley Chamber of Commerce, welcomed Nanoviricides to
Shelton. Paul Dorfman, Managing Director, Global Corporate Clients
Group of New York Stock Exchange said that NYSE was very pleased
that NanoViricides, Inc. chose to up-list to this exchange, and
expressed that NYSE extends continuing support to its clients
including NanoViricides, Inc.
Dr. Eugene Seymour, CEO of the Company, offered closing remarks.
He juxtaposed the extremely high levels of effectiveness observed
for nanoviricides drug candidates with similarly dramatic
effectiveness that penicillin had demonstrated in the first patient
treated in the USA at the Yale University hospital in 1942. He said
that the nanoviricides technology had the promise of being as
transformative against viral diseases, as penicillin has been
against bacterial diseases.
Several additional important community members also attended the
event. CTInnovations’ Director of Strategic Partnerships, Ms. Deb
Santy, said that this facility could have strategic implications
for Pharma start-ups in Connecticut. Key members of Shelton’s City
Government were present including Mayor Mark Lauretti, Board of
Aldermen President John Anglace, Police Chief Joel Hurliman, and
Planning & Zoning Commission Chairman Ruth Parkins.
Professor Jeffrey Sonnenfeld, Senior Associate Dean for
Executive Programs & Lester Crown Professor in the Practice of
Management, School of Management, Yale University, also attended
the event and congratulated the Company on its achievements.
Professor Thomas Lentz, the Company’s Scientific Advisory Board
Member and Professor Emeritus of Yale University attended the event
and said that this was truly a state of the art facility.
Several of the Company’s investors and associates from all over
the world also attended this invitation-only event.
All of the Company’s Directors, including Professor Milton
Boniuk, Professor Mukund Kulkarni, and Mr. Stanley Glick, attended
the event. The Company held a Board of Directors meeting after the
event in which the Board unanimously resolved to purchase the
facility from Inno-Haven, LLC, for an appropriate consideration to
be based on the actual capital expenditures, costs of finance, and
other project costs borne by Inno-Haven. The Board asked Dr.
Seymour to execute the purchase and related activities on behalf of
NanoViricides. Dr. Diwan recused himself from the board meeting as
he is controlling member of Inno-Haven, LLC. Dr. Diwan conveyed the
willingness of Inno-Haven for NanoViricides to acquire the building
rather than to lease it from Inno-Haven. NanoViricides, Inc. and
Inno-Haven, LLC have entered into a Memorandum of Understanding in
January 2013 which provides that Inno-Haven will build the facility
to NanoViricides’ specifications, and that NanoViricides will lease
the building with a right to purchase. No lease has been entered
into.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating
special purpose nanomaterials for viral therapy. The Company's
novel nanoviricide® class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although
it is not possible to predict or identify all such factors, they
may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective;
successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
NanoViricides, Inc.Amanda Schuon, 310-550-7200info@nanoviricides.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Aug 2024 to Sep 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Sep 2023 to Sep 2024